Changes in Hong Kong stocks | Jietai Technology-P (07666) rose nearly 8% and joined hands with Lilly to promote AI-driven extra-hepatic LNP delivery platform, partner companies are expected to undertake more industrial growth

The Zhitong Finance App learned that Jitai Technology-P (07666) rose nearly 8%. As of press release, it had risen 7.84% to HK$11.41, with a turnover of HK$55.991 million.

According to the news, recently, Jietai Technology-P and the world-renowned multinational pharmaceutical company Lilai reached a partnership with the largest AI-driven extra-hepatic LNP delivery platform in the world. It is also the first generative AI-LNP platform strategic cooperation in China. In this major strategic cooperation with a total cost of up to 1.1 billion US dollars, the two sides will focus on research and discovery of novel LNP (lipid nanoparticle) delivery solutions to explore tissue-specific delivery solutions that support various treatment models.

CITIC Construction Investment believes that as AI model iteration speeds up, the number of single design candidates increases, and more pharmaceutical companies embed AI in early R&D processes, demand for wet experiments is expected to continue to grow, and industrial chain links such as gene synthesis, protein expression, scientific research reagents, and CRO are expected to continue to benefit from the incremental market brought about by the increase in the penetration rate of AI pharmaceuticals. Service providers with high-throughput, automated, standardized testing, and structured data delivery capabilities are more likely to undertake incremental growth. The bank believes that the AI pharmaceutical industry has broad room for long-term growth, and Jietai Technology is expected to benefit as an AI pharmaceutical standard.